Carbonyl stress and diabetic complications

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 9, 2003, Pages 1150-1158

  Miyata, Toshio ^a   Ishikawa, Naoyoshi ^a   van Ypersele de Strihou, Charles ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Advanced glycosylation end products; Carbonyl stress; Diabetes mellitus; Oxidative stress

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXOTHIAZOLIDIN 5 YL ACETANILIDE; ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; CANDESARTAN; CARBONYL DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE; GLYCOSYLATED PROTEIN; GLYOXAL; HYDRALAZINE; HYDRAZINE; HYDRAZINE DERIVATIVE; INSULIN; IRBESARTAN; LACTOYLGLUTATHIONE LYASE; LOSARTAN; OLMESARTAN; PENTOSIDINE; PYRIDOXAL; PYRIDOXAMINE; RAMIPRIL; RECOMBINANT ENZYME; STREPTOZOCIN; TEMOCAPRILAT; TERMISARTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASCULOTROPIN;

ATHEROSCLEROSIS; BIOSYNTHESIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; DETOXIFICATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG BINDING; GENETIC ENGINEERING; HUMAN; HYPOTHESIS; NONHUMAN; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PYRIDOXINE DEFICIENCY; REVIEW; STRUCTURE ACTIVITY RELATION; TIME; TREATMENT PLANNING; UREMIA;

DIABETES COMPLICATIONS; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; OXIDATIVE STRESS;

EID: 0142093132     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.178     Document Type: Review

References (81)

1. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984; 81:583-7.
2. Yang Z, Makita Z, Horii Y, Brunelle S, Cerami A, Sehajpal P, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174:515-24.
3. Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986; 314:403-8.
4. E-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986; 261:4889-94.
5. Sell DR, Monnier VM. Structure elucidation of a senescence cross-link from human extracellular matrix. J Biol Chem 1989; 264:21597-602.
6. Njoroge FG, Sayre LM, Monnier VM. Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. Carbohydr Res 1987; 167: 211-20.
7. Nakamura K, Hasegawa T, Fukunaga Y, Ienaga K. Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of N-acetyl-L-lisyne with D-glucose. J Chem Soc Chem Commun 1992; 14:992-4.
8. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996; 11 Suppl 5:41-7.
9. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, et al. Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 1997; 51:187-94.
10. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992; 267:5133-8.
11. Taneda S, Monnier VM. ELISA of pentosidine, an advanced glycation end product, in biological specimens. Clin Chem 1992; 40:1766-73.
12. Izuhara Y, Miyata T, Ueda Y, Suzuki D, Asahi K, Inagi R, et al. A sensitive and specific ELISA for plasma pentosidine. Nephrol Dial Transplant 1999; 14:576-80.
13. E-(carboxymethyl) lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 1995; 34:10872-8.
14. E-(carboxymethyl) lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996; 35:8075-83.
15. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet SM, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343:1519-22.
16. Miyata T, Fu MX, Kurokawa K, van Ypersele de Strihou C, Thorpe SR, Baynes JW. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998; 54:1290-5.
17. E-(carboxymethyl) lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271:9982-6.
18. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992; 41:153-9.
19. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996; 93:2353-8.
20. Dyer DG, Dunn JA, Thorpe SR, Bailie KE, Lyons TJ, McCance DR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91:2463-9.
21. Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992; 41:1286-92.
22. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993; 91:2470-8.
23. Sugiyama S, Miyata T, Ueda Y, Tanaka H, Maeda K, Kawashima S, et al. Plasma level of pentosidine, an advanced glycation end product, in diabetic patients. J Am Soc Nephrol 1998; 9:1681-8.
24. Miyata T, Ueda Y, Shinzato T, Iida Y, Tanaka S, Kurokawa K, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996; 7:1198-206.
25. Miyata T, Ishikawa S, Asahi K, Inagi R, Suzuki D, Horie K, et al. 2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide (OPB-9195) inhibits the neointima proliferation of rat carotid artery following balloon injury: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 1999; 445:202-6.
26. Kawada N, Moriyama T, Ando A, Fukunaga M, Miyata T, Kurokawa K, et al. Increased oxidative stress in mouse kidneys with unilateral ureteral obstruction. Kidney Int 1999; 56:1004-13.
27. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001; 107:799-801.
28. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997; 12:255-8.
29. Miyata T, Kurokawa K, van Ypersele de Strihou C. Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000; 58 Suppl 76:S120-5.
30. Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1:150-61.
31. Miyata T, Wada Y, Cai Z, Iida Y, Horie K, Yasuda Y, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997; 51:1170-81.
32. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AN, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49:1304-13.
33. Ueda Y, Miyata T, Hashimoto T, Yamada H, Izuhara Y, Sakai H, et al. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. Biochem Biophys Res Commun 1998; 245:785-90.
34. Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynes JW. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. J Clin Invest 1997; 100:839-46.
35. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997; 100:2995-3004.
36. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107:853-60.
37. in long-term uremic complications. Kidney Int 1999; 55:389-99.
38. Thornalley PJ. Advanced glycation and development of diabetic complications: unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 1996;3:149-66.
39. Bravi MC, Pietrangeli P, Laurenti O, Basili S, Cassone-Faldetta M, Ferri C, et al. Polyol pathway activation and glutathione redox status in non-insulin-dependent diabetic patients. Metabolism 1997; 46:1194-8.
40. Travis SF, Morrison AD, Clements RSJ, Winegrad AI, Osaki FA. Metabolism of glucose in human erythrocytes by the polyol pathway. J Clin Invest 1972; 50:2104-12.
41. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, et al. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 2001; 60:2351-9.
42. Inagi R, Miyata T, Ueda Y, Yoshino A, Nangaku M, van Ypersele de Strihou C, Kurokawa K. Efficient in vitro lowering of carbonyl stress by the glyoxalase system in conventional glucose peritoneal dialysis fluid. Kidney Int 2002; 62: 679-87.
43. Miyata T, Kurokawa K, Van Ypersele De Strihou C. Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000; 11:1744-52.
44. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;276:10017-25.
45. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of protein by glucose. Biochemistry 1995;34:3702-9.
46. Hayashi T, Namiki M. Role of sugar fragmentation in the Maillard reaction. In: Fujimaki M, Namiki M, Kato H, editors. Amino-carbonyl reaction in food and biological systems. Amsterdam: Elsevier Press, 1986:29-38.
47. E-(carboxymethyl) lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990; 29:10964-70.
48. Esterbauer H, Schuer RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehyde. Free Radic Biol Med 1991; 11:81-128.
49. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR. The advanced glycation end product, N-epsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 1996; 271:9982-6.
50. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Suzuki D, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 1998; 95: 4882-7.
51. Anderson MM Hazen SL, Hsu FF, Heinecke JW. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanol, and acrolein: a mechanism for the generation of highly reactive α-hydroxy and α β-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 1997; 99:424-32.
52. Meng J, Sakata N, Imanaga Y, Tachikawa Y, Chihara J, Takebayashi S. Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure. Clin Nephrol 1999; 51:280-9.
53. Suzuki D, Miyata T, Saotome N, Horie K, Inagi R, Yasuda Y, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol 1999;10:822-32.
54. Miyata T, Ueda Y, Yamada Y, Izuhara Y, Wada T, Jadoul M, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-56.
55. McLellan AC, Phillips SA, Thornalley PJ. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. Anal Biochem 1992; 206:17-23.
56. Gallou G, Ruelland A, Legras B, Maugendre D, Allannic H, Cloarec L. Plasma malondialdehyde in type 1 and type 2 diabetic patients. Clin Chim Acta 1993; 214:227-34.
57. Beisswenger P, Lal S, Howell S, Stevens R, Siegel A, Yeo K, Randall W, et al. The role of 3-deoxyglucosone and the activity of its degradative pathways in the etiology of diabetic microvascular disease. In: O'Brien J, Nursten HE, Crabbe MJC, Ames JM, editors. The Maillard reaction in foods and medicine. Cambridge, U.K.: Royal Society of Chemistry, 1998:298-303.
58. Takata K, Horiuchi S, Araki N, Shiga M, Saitoh M, Morino Y. Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J Biol Chem 1988; 152:14819-25.
59. E-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274:31740-9.
60. Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, et al. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463:260-4.
61. Akhand AA, Kato M, Suzuki H, Liu W, Du J, Hamaguchi M, et al. Carbonyl compounds cross-link cellular proteins and activate protein-tyrosine kinase p60c-Src. J Cell Biochem 1999; 72:1-7
62. Akhand AA, Hossain K, Mitsui H, Kato M, Miyata T, Inagi R, et al. Glyoxal and methylglyoxal trigger distinct signals for map family kinases and caspase activation in human endothelial cells. Free Radic Biol Med 2001; 31:20-30.
63. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 2002; 61:375-86.
64. Ishikawa N, Miyata T, Ueda Y, Inagi R, Izuhara Y, Yuzawa H, et al. Affinity adsorption of glucose degradation products improves the biocompatibility of conventional peritoneal dialysis fluid. Kidney Int 2003; 63:331-9.
65. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32.
66. Nakamura S, Makita Z, Ishikawa S, Yasumura K, Fujii W, Yanagisawa K, et al. Progression of nephropathy in spontaneous diabetic rats is prevented by OPB-9195, a novel inhibitor of advanced glycation. Diabetes 1997; 46:895-9.
67. Miyata T, Ueda Y, Asahi K, Izuhara Y, Inagi R, Saito A, et al. Mechanism of the inhibitory effect of OPB-9195 ((±)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide) on advanced glycation end product and advanced lipoxidation end product formation. J Am Soc Nephrol 2000; 11:1719-25.
68. Miyata T, Horie K, Ueda Y, Fujita Y, Izuhara Y, Hirano H, et al. Advanced glycation and lipoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 2000; 58:425-35.
69. Taguchi T, Sugiura M, Hamada Y, Miwa I. In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate. Biochem Pharmacol 1998;55:1667-71.
70. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem Biophys Res Commun 1996; 220:113-9.
71. Onorato JM, Jenkins AJ, Thorpe SR, Baynes JW. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J Biol Chem 2000; 275:21177-84.
72. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW, Thorpe SR, Baynes JW. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61:939-50.
73. Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 2002; 51:2826-32.
74. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, et al. Angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002; 13: 2478-87.
75. Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N. Insulin-independent diabetes mellitus (type II) spontaneous hypertensive/NIH corpulent rat. Am J Pathol 1986; 123:398-400.
76. Nangaku M, Miyata T, Sada T, Mizuno M, Inagi R, Ueda Y, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14:1212-22.
77. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002; 51:3274-82.
78. Wilkinson-Berka JL, Kelly DJ, Koerner SM, Jaworski K, Davis B, Thallas V, et al. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) 27 rat. Diabetes 2002; 51:3283-9.
79. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40:1328-34.
80. Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60:228-34.
81. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-8.